<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Beni Suef Univ J Basic Appl Sci</journal-id><journal-id journal-id-type="iso-abbrev">Beni Suef Univ J Basic Appl Sci</journal-id><journal-title-group><journal-title>Beni-Suef University Journal of Basic and Applied Sciences</journal-title></journal-title-group><issn pub-type="ppub">2314-8535</issn><issn pub-type="epub">2314-8543</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7841026</article-id><article-id pub-id-type="publisher-id">95</article-id><article-id pub-id-type="doi">10.1186/s43088-021-00095-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8104-9046</contrib-id><name><surname>Kothandan</surname><given-names>Ram</given-names></name><address><email>ram.k.bt@kct.ac.in</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Rajan</surname><given-names>Cashlin Anna Suveetha Gnana</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Arjun</surname><given-names>Janamitra</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Raj</surname><given-names>Rejoe Raymond Michael</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Syed</surname><given-names>Sowfia</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.252262.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0613 6919</institution-id><institution>Bioinformatics Laboratory, Department of Biotechnology, </institution><institution>Kumaraguru College of Technology, </institution></institution-wrap>Coimbatore, India </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>1</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>10</volume><issue>1</issue><elocation-id>9</elocation-id><history><date date-type="received"><day>2</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The present pandemic situation due to coronavirus has led to the search for newer prevention, diagnostic, and treatment methods. The onset of the corona infection in a human results in acute respiratory illness followed by death if not diagnosed and treated with suitable antiretroviral drugs. With the unavailability of the targeted drug treatment, several repurposed drugs are being used for treatment. However, the side-effects of the drugs urges us to move to a search for newer synthetic- or phytochemical-based drugs. The present study investigates the use of various phytochemicals virtually screened from various plant sources in Western Ghats, India, and subsequently molecular docking studies were performed to identify the efficacy of the drug in retroviral infection particularly coronavirus infection.</p></sec><sec><title>Results</title><p id="Par2">Out of 57 phytochemicals screened initially based on the structural and physicochemical properties, 39 were effectively used for the docking analysis. Finally, 5 lead compounds with highest hydrophobic interaction and number of H-bonds were screened. Results from the interaction analysis suggest Piperolactam A to be pocketed well with good hydrophobic interaction with the residues in the binding region R1. ADME and toxicity profiling also reveals Piperolactam A with higher LogS values indicating higher permeation and hydrophilicity. Toxicity profiling suggests that the 5 screened compounds to be relatively safe.</p></sec><sec><title>Conclusion</title><p id="Par3">The in silico methods used in this study suggests that the compound Piperolactam A to be the most effective inhibitor of S-protein from binding to the GRP78 receptor. By blocking the binding of the S-protein to the CS-GRP78 cell surface receptor, they can inhibit the binding of the virus to the host.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s43088-021-00095-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>In silico drug design</kwd><kwd>Virtual screening</kwd><kwd>Retroviral infection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">COVID-19, an infectious disease caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) has become an unexpected threat to the human population. With the exponential raising of the infection by followed increasing mortality rate day by day, the World Health Organization ((WHO)) has reported active cases 14,348,858 and death of 603,691 humans on 20th July 2020 [<xref ref-type="bibr" rid="CR1">1</xref>]. The threat has forced a major responsibility to scientific society in the search for new diagnostic methods, treatment, and preventive solutions. Existing repurposed drugs have been neglected by the medical community due to associated side effects [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par13">CoV belongs to the family <italic>Coronaviridae</italic> with a large RNA genome of 30 kb, positive-sensed and non-segmented [<xref ref-type="bibr" rid="CR3">3</xref>]. The virion structure contains four parts of protein which are Spike proteins (S-proteins), membrane proteins (M-proteins), envelope proteins (E-proteins), and nucleocapsid proteins (N-proteins). Of these S-proteins play a major role in transfer of virion particles from the virus to the host cells using ACE2 receptor [<xref ref-type="bibr" rid="CR4">4</xref>]. Although various literature has highlighted the importance of other proteins; the S-protein is currently well studied and has been as a potent drug target [<xref ref-type="bibr" rid="CR5">5</xref>]. The S-protein exhibit in a homo-trimeric state with N-terminal glycosylation in which the S-polypeptide chain cleaved into two subunits S1 and S2 (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)&#x000a0;[<xref ref-type="bibr" rid="CR3">3</xref>]. The S1 subunit with the larger receptor binding domain and the S2 subunit which induces the membrane fusion polypeptides forming the six helix bundle which results in complete fusion and insertion of viral genome to the host cell cytosol [<xref ref-type="bibr" rid="CR6">6</xref>]. Hence, structural analysis on the S-protein could reveal possible mechanisms by which the viral replication could be terminated/controlled [<xref ref-type="bibr" rid="CR7">7</xref>].
<fig id="Fig1"><label>Fig. 1</label><caption><p>3D structure of 6X6P (Spike Protein, Trimeric structure) with chain A&#x000a0;(Red), chain B (green), and chain C (magenta). Binding region 1 with its amino acids is highlighted</p></caption><graphic xlink:href="43088_2021_95_Fig1_HTML" id="MO1"/></fig></p><p id="Par14">Till date, many studies are involved in targeting ACE2 receptor (angiotensin converting enzyme-2), an amino peptidase which found to act as a cellular gateway for the entry of viral RNA into the cells using the S-proteins present in the surface of the virus [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. But ACE2 receptor is not only the gateway present on cell membrane to carry this virion into the cells, there are other cellular surface proteins which could also take this role. One such protein is glucose regulated protein 78 (GRP78) residing in lumen of endoplasmic reticulum (ER), a heat shock protein with a molecular weight of 78 kDa and a molecular chaperone present in all eukaryotic cells. The major role of GRP78 is protein folding, unfolding, and resisting aggregation of proteins in cytosol [<xref ref-type="bibr" rid="CR9">9</xref>]. The ER-protein when overexpressed escape the KDEL motif receptors which responsible for retention in ER due to its saturation or down regulation and get translocated in the cell membrane and act as cell surface GRP78 receptor (CS-GRP78 receptor) which pose the potential threat to our system for viral entry. Hypoxia, glucose starvation, and tumor causes ER stress which thus upregulate the GRP78 genes and result in over production of GRP78 [<xref ref-type="bibr" rid="CR10">10</xref>]. Misfolded protein accumulation also results in overexpression of this protein mostly reported in neurodegenerative disorders and conditions like Alzheimer, Parkinson&#x02019;s disease, and prion protein disease [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par15">CS-GRP78 acts as a multifunctional receptor and binds plenty of proteins and other compounds and activates several pathways which have negative impact on the cells like apoptosis [<xref ref-type="bibr" rid="CR12">12</xref>]. Several studies reveal that this protein has been responsible for many types of viral entry. In entry of CoxsackieVirus A9 CS-GRP78 involved as the co-receptor along with MHC Class 1 molecule on cell surface [<xref ref-type="bibr" rid="CR13">13</xref>]. GRP78 studies reported an important host cell factor in the entry of Japanese Encephalitis Virus into the host cells [<xref ref-type="bibr" rid="CR14">14</xref>]. Studies report that along with Dipeptidyl-peptidase 4 (DPP4), CS-GRP78 involved in the entry of MERS-CoV and reported that introduction of MERS-CoV into cells upregulate the GRP78 genes. Upregulation of GRP78 genes results in overproduction of GRP78 which help in both viral entry and development [<xref ref-type="bibr" rid="CR15">15</xref>]. Conditions in which the primary receptor expression in host is low CS-GRP78 act as the main alternate door for the viral entry. Thus, inhibiting or reducing CS-GRP78 mediated entry of SARS-CoV-2 is essentially equivalent to inhibiting the ACE2 mediated receptor entry [<xref ref-type="bibr" rid="CR16">16</xref>]. Protein-protein docking studies established the possible binding site where these two proteins could form complex with good HADDOCK Score, PRODIGY Binding affinity, H-bonds, and hydrophobic interaction. It would be a good approach, if we could block the region of S-protein which is responsible for binding to the CS-GRP78 receptor.</p><p id="Par16">Considering the pandemic situation, several health organization, and nations in the aim of developing antiviral agents are repurposing drugs like Lopinavir (HIV), Hydroxychloroquinone (Malaria) against COVID [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In general, repurposed pose variable target mechanisms and lack effectiveness for coronavirus strain. On the other hand, antiviral drugs also exhibit adverse side effects, which directly and indirectly affect human health [<xref ref-type="bibr" rid="CR19">19</xref>]. To overcome this shortfall, the development of plant-based drugs and treatment strategies with minimal side-effects are expected [<xref ref-type="bibr" rid="CR20">20</xref>]. Potentially phytochemicals, which serves as an infinite resource for drug development and novel pharmacophore may be benefited as a therapeutic agent against corona viruses. Their therapeutic applications against diverse viruses can be explained by various antiviral mechanisms such as inhibition of replication process [<xref ref-type="bibr" rid="CR21">21</xref>] and blocking the binding of virus to the host [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par17">Ancient Indian traditional techniques used several plant parts to treat various infections and disease conditions [<xref ref-type="bibr" rid="CR23">23</xref>]. Plant parts used in the treatment was experimentally proven to pose effective medicinal properties, further studies on their crude extract and compounds extracted from the plant proved that the extracts are contained with secondary metabolites like alkaloids, flavonoids, phenols, and chalcones and were termed as phytochemicals. A large number of phytochemicals pose antimicrobial, antiviral, and antioxidant properties [<xref ref-type="bibr" rid="CR24">24</xref>]. These plant parts which were used to treat the disease or infection were later experimentally proven for their medicinal properties [<xref ref-type="bibr" rid="CR25">25</xref>]. Several literature studies and promising diverse biological assays reveal that a large amount of phytochemicals can be utilized as an effective treatment for retroviral infections. Recently, phytochemicals are used as an inhibitory material for viral infection including HIV, influenza, common cold, etc. [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par18">In this study, an attempt has been made to virtually screen potential phytochemicals with high effectiveness particularly from plants originated from Western Ghats, India. Intensive literature survey has been made prior to the screening of phytochemicals. Effectiveness of the screened compounds were validated based on the in silico docking technique by binding to the S-protein of SARS-CoV-2 and ranked based on the interaction analysis between the protein-receptor complex.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Computational platform</title><p id="Par19">All computational analyses were performed on Linux Mint 18 platform in a Dell T20 server on Intel Xeon Quad Core 3.2 Hz.</p></sec><sec id="Sec4"><title>Receptor preparation</title><p id="Par20">The SARS-CoV-2 S-protein (PDB ID: 6X6P at 3.2 <italic>&#x000c5;</italic>) with the spike glycoprotein was downloaded from RCSB Protein Bank (PDB). The protein is a trimeric viral fusion protein with subunits S1 and S2. S1 contains the receptor binding protein (RBD) responsible for host cell receptor binding and the S2 subunit facilitates the membrane fusion between the viral and host cell membranes. The viral protein contains 1274 amino acids and weighs 434.87 kDa. For the purpose of the study, we utilized only Chain A from the S-protein for docking analysis. Protein visualization and manipulation of the structures was done using UCSF Chimera [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec5"><title>Binding-site preparation</title><p id="Par21">The prediction of binding site was done with respect to the available literature [<xref ref-type="bibr" rid="CR29">29</xref>] and then verified based on the presence of hydrophobic regions on the surface of the protein. For the purpose of the study, we utilized the same binding site between the S-protein and CS-GRP78, since our main aim is to block the binding of S-protein to the ER protein [<xref ref-type="bibr" rid="CR29">29</xref>]. The hydrophobicity of the protein is calculated using GRAVY server [<xref ref-type="bibr" rid="CR30">30</xref>]. The S-protein contains four hydrophobic regions in the receptor binding domain (RBD) ranging from 318 to 510 as of the S1 subunit. The binding energy values obtained from protein binding energy prediction (PRODIGY) [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec6"><title>Screening for phytochemicals</title><p id="Par22">Phytochemicals with antiviral, antimicrobial, and antioxidant properties were screened based on the previous literature and were sorted, filtered based on their geographical origin [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR33">33</xref>]. More than 100 compounds were initially screened. 3D and 2D structures were downloaded from PUBCHEM database [<xref ref-type="bibr" rid="CR34">34</xref>] and drugbank.ca [<xref ref-type="bibr" rid="CR35">35</xref>] in both SDF and Simplified Molecular Input Line Entry System (SMILES) format [<xref ref-type="bibr" rid="CR36">36</xref>] for further screening procedures. In order to select the potential drug-like compounds, several filters were applied on the structures.</p><p id="Par23">Initially, LIPINSKI rule of five (RO5) was applied to screen potential drug-like compounds [<xref ref-type="bibr" rid="CR37">37</xref>]. Drug-like compounds screened from RO5 was further fed into SWISS-ADME server for screening based on the pharmacokinetics, drug-likeliness, and medicinal chemistry friendliness of small molecules [<xref ref-type="bibr" rid="CR38">38</xref>]. In addition, the physicochemical properties and the drugability of the selected compounds were also predicted with SWISS-ADME server. Hydroxychloroquinone (HCQ) (PUBCHEM ID: 3652), a well-known retro viral drug was used as a standard throughout the studies [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec7"><title>Multiple ligand docking</title><p id="Par24">For the purpose of study, Autodock was employed for docking simulations [<xref ref-type="bibr" rid="CR40">40</xref>]. Initially, water molecules and hetero atoms were removed from the structures [<xref ref-type="bibr" rid="CR41">41</xref>]. Addition of gasteiger charges and H-bond was carried out prior to the docking protocol. A grid box of 25 <italic>&#x000d7;</italic> 22 <italic>&#x000d7;</italic> 19 <italic>&#x000c5;</italic> was assigned on the surface of the receptor with respect to the identified active site. In this present study, multiple ligands have been screened against the receptor. Multiple ligand docking was carried out using PyRx in the Autodock environment [<xref ref-type="bibr" rid="CR42">42</xref>]. The docked structures were analyzed for root mean square deviation (RMSD), lowest energy conformer, and hydrogen bond (HB) interaction. 2D protein-ligand interaction profile was obtained using Protein Plus Server [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>] and Protein Ligand Interaction Profiler [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec8"><title>Physicochemical property of the bound ligand</title><p id="Par25">To validate the bound ligand with the receptor, the physicochemical and pharmacokinetic properties of the drug are analyzed using SWISS-ADME server [<xref ref-type="bibr" rid="CR38">38</xref>]. The toxicity profile is analyzed using admetSAR 2.0 [<xref ref-type="bibr" rid="CR46">46</xref>], which provides information on the ADMET properties. Screened compounds were subjected to Ghose filter [<xref ref-type="bibr" rid="CR47">47</xref>] and Muegge Filter [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par26">In the present study, 57 phytochemicals were initially screened based on their structural and physicochemical properties, later only 39 compounds were utilized for the docking analysis based on the various filters utilized during the course of the study. Binding sites were initially chosen based on the literature survey made on the target protein 6X6P. Potential binding sites were further selected based on the hydrophobic index obtained from GRAVY server. Results from GRAVY server indicate significant values for the four-binding region R1-R4 as &#x02212; 0.24, &#x02212; 0.3, &#x02212; 0.28, and &#x02212; 0.08, respectively. Binding sites were also considered based on their predicted binding energy by PRODIGY. Results from PRODIGY for the four binding regions R1&#x02013;R4 are &#x02212; 12.4, &#x02212; 9.8, &#x02212; 10.1, and &#x02013; 14 kcal/mol, respectively. Region 4 (R4) [&#x02212; 9.8 kcal/mol] and Region 1 (R1) [&#x02212; 12.4 kcal/mol] of the S-protein pose a higher hydrophobicity. However, R1 was considered for the potential binding site.</p><p id="Par27">Prior to the actual binding, the ligands are screened based on the RO5 and SWISS-ADME filters. Among the 39 finally screened compounds, only 5 compounds exhibited docking energy values above &#x02212; 8.9 to 8.3 kcal/mol for SARS-CoV-2 S-protein Region 1&#x000a0;(Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Among them, Tanshinone I exhibited an average docking score of &#x02212; 8.9 kcal/mol and Piperolactam A with a docking score of &#x02212; 8.3 kcal/mol ranked the strongest both in terms of binding energy and HB interaction. A list of all other ranked ligands based on the binding energy is listed in the Table <xref rid="Tab1" ref-type="table">1</xref>. The standard ligand, HCQ resulted in a docking score of &#x02212; 4.7 kcal/mol and was used to compare other phytochemicals docked with the S-protein.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Dock Scores obtained from Autodock Pyrex of Screened Ligands</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligand</th><th>Binding energy<break/>(kcal/mol)</th><th>Molecular weight<break/>(g/mol)</th><th>Rotatable bonds</th><th>HB acceptor</th><th>HB Donar</th><th>TPSA (&#x000a0;&#x000c5;<sup>2</sup>)</th></tr></thead><tbody><tr><td>Tanshinone I</td><td>-8.9</td><td>276.29</td><td>0</td><td>3</td><td>0</td><td>47.28</td></tr><tr><td>Ellipticine</td><td>-8.4</td><td>246.31</td><td>0</td><td>1</td><td>1</td><td>28.68</td></tr><tr><td>Anabsinthin</td><td>-8.4</td><td>496.64</td><td>0</td><td>6</td><td>1</td><td>82.06</td></tr><tr><td>Camptothecin</td><td>-8.3</td><td>348.35</td><td>1</td><td>5</td><td>1</td><td>81.42</td></tr><tr><td>Piperolactam A</td><td>-8.3</td><td>265.26</td><td>1</td><td>3</td><td>2</td><td>62.32</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Virtually screened ligands from PubChem compounds</p></caption><graphic xlink:href="43088_2021_95_Fig2_HTML" id="MO2"/></fig></p><p id="Par28">The HCQ-S-protein complex has two HB interactions with ARG355 and TYR396 which contribute to the hydrophobic interactions. In comparison with HCQ, Tanshinone I has the highest binding affinity of &#x02212; 8.9 kcal/mol compared to all other compounds and has one HB of distance 2.38 <italic>&#x000c5;</italic> with the acceptor atom O2 of ASN343. Tanshinone I also formed a good hydrophobic interaction with the neighboring amino acids <italic>viz.,</italic> PHE338, PHE342, VAL367, LEU368, and PHE374 (Table <xref rid="Tab2" ref-type="table">2</xref>), whereas the second lead compound Piperolactam A with binding affinity &#x02212; 8.3 kcal/mol is found to form two HB interaction with the S-protein in which both bonds are from ASP364 to the compound with a distance of 1.99 <italic>&#x000c5;</italic> and 2.05 <italic>&#x000c5;&#x000a0; </italic>(Fig. <xref rid="Fig3" ref-type="fig">3</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>HB Interaction with the Screened Ligands</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Ligands</th><th>Hydrogen bonds</th><th>Hydrogen Bond Interaction</th><th>Distance H-A (A<sup>2</sup>)</th></tr></thead><tbody><tr><td>Tanshinone I</td><td>1</td><td>ASN A: 343</td><td>2.3</td></tr><tr><td>Ellipticine</td><td>0</td><td>-</td><td>-</td></tr><tr><td>Anabsinthin</td><td>1</td><td>ASP A:364</td><td>2.68</td></tr><tr><td>Camptothecin</td><td>2</td><td>GLY A:339, ASP A:364</td><td>2.83,3.21</td></tr><tr><td>Piperolactam A</td><td>2</td><td>ASP A:364, ASP A:364</td><td>1.99, 2.05</td></tr><tr><td>Hydroxychloroquine</td><td>2</td><td>355 A:ARG,466 A:ARG</td><td>2.27,2.37</td></tr></tbody></table></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Piperolactam A docked with S-protein. <bold>a</bold> Surface image of Piperolactam A docked with the Region 1 of 6X6P S-protein. <bold>b</bold> 2D Interaction map of the Piperolactam A with the S-protein. Interaction profiles indicate two H-bond with ASP364</p></caption><graphic xlink:href="43088_2021_95_Fig3_HTML" id="MO3"/></fig></p><p id="Par29">Compounds with good ADME parameters are suitable for the drug discovery process. Analysis of the lipophilicity of the screened compounds showed positive values which indicates enhanced rate of adsorption [<xref ref-type="bibr" rid="CR49">49</xref>] as described in <xref rid="MOESM1" ref-type="media">supplementary material</xref>.</p></sec><sec id="Sec10"><title>Discussion</title><p id="Par30">In this present study, although during the selection and validation of the predicted binding sites, both Region R1 and R4 resulted as potential binding sites among the four predicted sites. Based on the hydrophobicity index, R4 is marked with higher index values; however, the site fails to show minimum interaction with the known receptor CS-GRP78 [<xref ref-type="bibr" rid="CR10">10</xref>]. The binding affinity of R4 is &#x02013; 14 kcal/mol which is much lower than the R1 with &#x02212; 12.4 kcal/mol. Based on the binding affinity values, R1 is considered to be a potential binding site for the screened ligands. The binding site involves the residues of ASN343, ASP364, GLY339, ARG355, and ARG466. Additional amino acids at the active site are PHE338, VAL367, LEU368, PHE342, PHE337, and TYR396 (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par31">With respect to screened ligands, the hydrophilicity factor (LogS) of Camptothecin (&#x02212; 3.49) and Piperolactam A (&#x02212; 3.87) showed higher LogS values (high permeation and hydrophilicity) than the other screened compounds [<xref ref-type="bibr" rid="CR50">50</xref>]. Among the screened compounds, Ellipticine (&#x02212; 5.05) showed a less LogS value indicating a poor permeation. Similarly, anabsinthin acts a good substrate for P-glycoprotein, which is highly susceptible to changes in pharmacokinetics by acting as either P-glycoprotein inducer or inhibitors [<xref ref-type="bibr" rid="CR51">51</xref>]. Thus, anabsinthin could cross the blood-brain barrier (BBB) and it may render the compound functionally inactive [<xref ref-type="bibr" rid="CR52">52</xref>]. Further, anabsinthin could not satisfy Ghose rule [<xref ref-type="bibr" rid="CR47">47</xref>] of drug-likeness with three violations and Muegge rule [<xref ref-type="bibr" rid="CR48">48</xref>] of drug-likeness with one violation. Piperolactam A showed a good pharmacokinetics property with good GI absorption, cross BBB, affects only two cytochrome P450 enzymes compared to others and is also not a substrate for P-glycoprotein. The phytochemical compound Piperolactam A has synthetic accessibility of 2.02 which makes it at ease of synthesis of the compound in spite of an alert in the Brenk filter. Whereas Camptothecin was found with no violations but its synthetic accessibility is of higher value than that of Piperolactam A. Toxicity analysis is essential for a drug to know the potential hazard to be produced by it. The predicted toxicity profile from our study reveals that all the compounds are relatively safe.</p><p id="Par32">Results from the docking analysis suggest that the Piperolactam A pocketed well with good hydrophobic interaction with residues PHE338, PHE342, and VAL367as well &#x000a0;(Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Based on the results obtained, the study suggests use of Piperolactam A as a potential antiretroviral drug against SARS-CoV-2. Piperolactam, an aristolactam isolated from Piper betle Linn and its abundant availability in Western Ghats [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par33">In this study, five phytochemical compounds with antiretroviral properties were screened against the receptor 6X6P. These compounds displayed appreciable pharmacokinetic and physicochemical properties. ADMET analyses of these compounds reveal that the compound Piperolactam A from <italic>Piperaceae</italic> family to be most effective in the inhibition of S-protein from binding to the CS-GRP78 receptor.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec12"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="43088_2021_95_MOESM1_ESM.pdf"><caption><p><bold>Additional file 1.</bold>
</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACE2</term><def><p id="Par4">Angiotensin converting enzyme-2</p></def></def-item><def-item><term>ER</term><def><p id="Par5">Endoplasmic reticulum</p></def></def-item><def-item><term>DPP4</term><def><p id="Par6">Dipeptidyl-peptidase 4</p></def></def-item><def-item><term>CS-GRP78</term><def><p id="Par7">Cell surface glucose receptor protein 78</p></def></def-item><def-item><term>HIV</term><def><p id="Par8">Human immuno-deficiency virus</p></def></def-item><def-item><term>PRODIGY</term><def><p id="Par9">Protein energy binding prediction</p></def></def-item><def-item><term>SMILES</term><def><p id="Par10">Simplified Molecular Input Line Entry System</p></def></def-item><def-item><term>BBB</term><def><p id="Par11">Blood-brain barrier</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>RK designed the study, carried out research, and wrote manuscript. CSA contributed to study design and manuscript writing. JA and SS advised on phytochemical virtual screening and editing manuscript. RR contributed to the docking analysis and interpretation. All authors have read and approved the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data used in the study is given as supplementary data.</p></notes><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par34">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par35">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par36">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrague</surname><given-names>LJ</given-names></name><name><surname>de Los Santos</surname><given-names>J</given-names></name></person-group><article-title>COVID-19 anxiety among frontline nurses: predictive role of organisational support, personal resilience and social support</article-title><source>J Nurs Manag.</source><year>2020</year><volume>28</volume><issue>7</issue><fpage>1653</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1111/jonm.13121</pub-id><?supplied-pmid 32770780?><pub-id pub-id-type="pmid">32770780</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>M</given-names></name><name><surname>Parihar</surname><given-names>N</given-names></name><name><surname>Soni</surname><given-names>SL</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name></person-group><article-title>Drug repurposing: an overview</article-title><source>Asian J Pharm Res Dev</source><year>2020</year><volume>8</volume><issue>4</issue><fpage>194</fpage><lpage>212</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astuti</surname><given-names>I</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response</article-title><source>Diabetes Metab Syndr</source><year>2020</year><volume>14</volume><issue>4</issue><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.020</pub-id><?supplied-pmid 32335367?><pub-id pub-id-type="pmid">32335367</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belouzard</surname><given-names>S</given-names></name><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Licitra</surname><given-names>BN</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title><source>Viruses.</source><year>2012</year><volume>4</volume><issue>6</issue><fpage>1011</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3390/v4061011</pub-id><?supplied-pmid 22816037?><pub-id pub-id-type="pmid">22816037</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roshanravan</surname><given-names>N</given-names></name><name><surname>Ghaffari</surname><given-names>S</given-names></name><name><surname>Hedayati</surname><given-names>M</given-names></name></person-group><article-title>Angiotensin converting enzyme-2 as therapeutic target in COVID-19</article-title><source>Diabetes Metab Syndr</source><year>2020</year><volume>14</volume><issue>4</issue><fpage>637</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1016/j.dsx.2020.05.022</pub-id><?supplied-pmid 32428864?><pub-id pub-id-type="pmid">32428864</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalathiya</surname><given-names>U</given-names></name><name><surname>Padariya</surname><given-names>M</given-names></name><name><surname>Mayordomo</surname><given-names>M</given-names></name><name><surname>Lisowska</surname><given-names>M</given-names></name><name><surname>Nicholson</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: a novel binding site</article-title><source>J Clin Med.</source><year>2020</year><volume>9</volume><issue>5</issue><fpage>1473</fpage><pub-id pub-id-type="doi">10.3390/jcm9051473</pub-id><?supplied-pmid 7290299?><pub-id pub-id-type="pmid">7290299</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prajapat</surname><given-names>M</given-names></name><name><surname>Sarma</surname><given-names>P</given-names></name><name><surname>Shekhar</surname><given-names>N</given-names></name><name><surname>Avti</surname><given-names>P</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><etal/></person-group><article-title>Drug targets for corona virus: a systematic review</article-title><source>Indian J Pharmacol.</source><year>2020</year><volume>52</volume><issue>1</issue><fpage>56</fpage><pub-id pub-id-type="doi">10.4103/ijp.IJP_115_20</pub-id><?supplied-pmid 32201449?><pub-id pub-id-type="pmid">32201449</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target</article-title><source>Intensive Care Med.</source><year>2020</year><volume>46</volume><issue>4</issue><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><?supplied-pmid 32125455?><pub-id pub-id-type="pmid">32125455</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>R</given-names></name><name><surname>Kao</surname><given-names>C</given-names></name></person-group><article-title>Cell surface GRP78 as a death receptor and an anticancer drug target</article-title><source>Cancers.</source><year>2019</year><volume>11</volume><issue>11</issue><fpage>1787</fpage><pub-id pub-id-type="doi">10.3390/cancers11111787</pub-id><?supplied-pmid 6896222?><pub-id pub-id-type="pmid">6896222</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>IM</given-names></name><name><surname>Abdelmalek</surname><given-names>DH</given-names></name><name><surname>Elfiky</surname><given-names>AA</given-names></name></person-group><article-title>GRP78: a cell&#x02019;s response to stress</article-title><source>Life Sci</source><year>2019</year><volume>226</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2019.04.022</pub-id><?supplied-pmid 30978349?><pub-id pub-id-type="pmid">30978349</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AS</given-names></name></person-group><article-title>The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress</article-title><source>Methods.</source><year>2005</year><volume>35</volume><issue>4</issue><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2004.10.010</pub-id><?supplied-pmid 15804610?><pub-id pub-id-type="pmid">15804610</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;nthal</surname><given-names>AH</given-names></name></person-group><article-title>Endoplasmic reticulum stress: its role in disease and novel prospects for therapy</article-title><source>Scientifica.</source><year>2012</year><volume>2012</volume><fpage>857516</fpage><pub-id pub-id-type="doi">10.6064/2012/857516</pub-id><?supplied-pmid 24278747?><pub-id pub-id-type="pmid">24278747</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name></person-group><article-title>Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting</article-title><source>Biochem J</source><year>2011</year><volume>434</volume><issue>2</issue><fpage>181</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1042/BJ20101569</pub-id><?supplied-pmid 21309747?><pub-id pub-id-type="pmid">21309747</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nain</surname><given-names>M</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Karmakar</surname><given-names>SP</given-names></name><name><surname>Paton</surname><given-names>AW</given-names></name><name><surname>Paton</surname><given-names>JC</given-names></name><name><surname>Abdin</surname><given-names>M</given-names></name><etal/></person-group><article-title>GRP78 is an important host factor for Japanese encephalitis virus entry and replication in mammalian cells</article-title><source>J Virol</source><year>2017</year><volume>91</volume><issue>6</issue><fpage>e02274</fpage><lpage>e02216</lpage><pub-id pub-id-type="doi">10.1128/JVI.02274-16</pub-id><?supplied-pmid 28053106?><pub-id pub-id-type="pmid">28053106</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>H</given-names></name><name><surname>Chan</surname><given-names>CM</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells</article-title><source>J Biol Chem.</source><year>2018</year><volume>293</volume><issue>30</issue><fpage>11709</fpage><lpage>11726</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.001897</pub-id><?supplied-pmid 29887526?><pub-id pub-id-type="pmid">29887526</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>DP</given-names></name><name><surname>Van Krieken</surname><given-names>R</given-names></name><name><surname>Carlos</surname><given-names>AJ</given-names></name><name><surname>Lee</surname><given-names>AS</given-names></name></person-group><article-title>The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection</article-title><source>J Infect</source><year>2020</year><volume>81</volume><issue>3</issue><fpage>452</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.06.017</pub-id><?supplied-pmid 32535155?><pub-id pub-id-type="pmid">32535155</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM (2020) Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. J Biomol Struct Dyn 16:1&#x02013;6. 10.1080/07391102.2020.1752802. Epub ahead of print. PMID: 32248766.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathy</surname><given-names>S</given-names></name><name><surname>Dassarma</surname><given-names>B</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Chabalala</surname><given-names>H</given-names></name><name><surname>Matsabisa</surname><given-names>MG</given-names></name></person-group><article-title>A review on possible modes of actions of Chloroquine/Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic</article-title><source>Int J Antimicrob Agents</source><year>2020</year><volume>56</volume><fpage>106028</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106028</pub-id><?supplied-pmid 32450198?><pub-id pub-id-type="pmid">32450198</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Ghildiyal R, Prakash V, Chaudhary V, Gupta V, Gabrani R (2020) Phytochemicals as antiviral agents: recent updates. In: Plant-derived Bioactives; Singapore: Springer, pp 279&#x02013;295</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>D</given-names></name><name><surname>Nandy</surname><given-names>S</given-names></name><name><surname>Mukherjee</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>D</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name></person-group><article-title>Moringa oleifera Lam. and derived phytochemicals as promising antiviral agents: a review</article-title><source>South Afr J Botany</source><year>2020</year><volume>129</volume><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.sajb.2019.07.049</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Kanwar</surname><given-names>S</given-names></name></person-group><article-title>Antiviral phytochemicals: an overview</article-title><source>Biochem Physiol.</source><year>2017</year><volume>6</volume><issue>2</issue><fpage>7</fpage><pub-id pub-id-type="doi">10.4172/2168-9652.1000220</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subudhi</surname><given-names>BB</given-names></name><name><surname>Chattopadhyay</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Current strategies for inhibition of chikungunya infection</article-title><source>Viruses.</source><year>2018</year><volume>10</volume><issue>5</issue><fpage>235</fpage><pub-id pub-id-type="doi">10.3390/v10050235</pub-id><?supplied-pmid 5977228?><pub-id pub-id-type="pmid">5977228</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>M</given-names></name><name><surname>Rastogi</surname><given-names>S</given-names></name><name><surname>Rawat</surname><given-names>A</given-names></name></person-group><article-title>Indian traditional ayurvedic system of medicine and nutritional supplementation</article-title><source>Evid Based Complement Alternat Med.</source><year>2013</year><volume>2013</volume><fpage>376327</fpage><?supplied-pmid 23864888?><pub-id pub-id-type="pmid">23864888</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Naithani R, Mehta RG, Shukla D, Chandersekera SN, Moriarty RM (2010) Antiviral activity of phytochemicals: a current perspective. In: Dietary Components and Immune Function. Humana Press, Totowa: Springer, pp 421&#x02013;468</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovska</surname><given-names>BB</given-names></name></person-group><article-title>Historical review of medicinal plants usage</article-title><source>Pharmacogn Rev</source><year>2012</year><volume>6</volume><issue>11</issue><fpage>1</fpage><pub-id pub-id-type="doi">10.4103/0973-7847.95849</pub-id><?supplied-pmid 22654398?><pub-id pub-id-type="pmid">22654398</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Meher</surname><given-names>B</given-names></name><name><surname>Purohit</surname><given-names>P</given-names></name><name><surname>Dash</surname><given-names>JJ</given-names></name></person-group><source>Probing phytochemicals as prospective antiviral agents against HIV-1 protease through structure-based virtual screening and molecular dynamics simulations</source><year>2020</year></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Hota DK, Nayak D, Swain S, Bhattacharyay D (2020) Capsicum derived phytochemicals against Shikimate dehydrogenase of haemophilus influenza causing bronchitis. J Pharm Res Intern 32(6):128&#x02013;131</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><etal/></person-group><article-title>UCSF Chimeraa visualization system for exploratory research and analysis</article-title><source>J Comput Chem</source><year>2004</year><volume>25</volume><issue>13</issue><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><?supplied-pmid 15264254?><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>IM</given-names></name><name><surname>Abdelmalek</surname><given-names>DH</given-names></name><name><surname>Elshahat</surname><given-names>ME</given-names></name><name><surname>Elfiky</surname><given-names>AA</given-names></name></person-group><article-title>COVID-19 spike-host cell receptor GRP78 binding site prediction</article-title><source>J Infect</source><year>2020</year><volume>80</volume><issue>5</issue><fpage>554</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.026</pub-id><?supplied-pmid 32169481?><pub-id pub-id-type="pmid">32169481</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ul Qamar</surname><given-names>MT</given-names></name><name><surname>Alqahtani</surname><given-names>SM</given-names></name><name><surname>Alamri</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name></person-group><article-title>Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants</article-title><source>J Pharm Anal</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.009</pub-id><pub-id pub-id-type="pmid">32296570</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silambarasan</surname><given-names>R</given-names></name><name><surname>Sureshkumar</surname><given-names>J</given-names></name><name><surname>Krupa</surname><given-names>J</given-names></name><name><surname>Amalraj</surname><given-names>S</given-names></name><name><surname>Ayyanar</surname><given-names>M</given-names></name></person-group><article-title>Traditional herbal medicines practiced by the ethnic people in Sathyamangalam forests of Western Ghats, India</article-title><source>Eur J Integrative Med</source><year>2017</year><volume>16</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.eujim.2017.10.010</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>PN</given-names></name><name><surname>Decruse</surname><given-names>S</given-names></name><name><surname>Radha</surname><given-names>R</given-names></name></person-group><article-title>Conservation of medicinal plants of Western Ghats, India and its sustainable utilization through in vitro technology</article-title><source>In Vitro Cell Dev Biology-Plant.</source><year>2011</year><volume>47</volume><issue>1</issue><fpage>110</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/s11627-011-9344-9</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatachalapathi</surname><given-names>A</given-names></name><name><surname>Sangeeth</surname><given-names>T</given-names></name><name><surname>Ali</surname><given-names>MA</given-names></name><name><surname>Tamilselvi</surname><given-names>SS</given-names></name><name><surname>Paulsamy</surname><given-names>S</given-names></name><name><surname>Al-Hemaidc</surname><given-names>FM</given-names></name></person-group><article-title>Ethnomedicinal assessment of Irula tribes of Walayar valley of Southern Western Ghats, India</article-title><source>Saudi J Biol Sci</source><year>2018</year><volume>25</volume><issue>4</issue><fpage>760</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2016.10.011</pub-id><?supplied-pmid 29740242?><pub-id pub-id-type="pmid">29740242</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Gindulyte</surname><given-names>A</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>S</given-names></name><etal/></person-group><article-title>PubChem 2019 update: improved access to chemical data</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D1102</fpage><lpage>D1109</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1033</pub-id><?supplied-pmid 30371825?><pub-id pub-id-type="pmid">30371825</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Feunang</surname><given-names>YD</given-names></name><name><surname>Guo</surname><given-names>AC</given-names></name><name><surname>Lo</surname><given-names>EJ</given-names></name><name><surname>Marcu</surname><given-names>A</given-names></name><name><surname>Grant</surname><given-names>JR</given-names></name><etal/></person-group><article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>D1</issue><fpage>D1074</fpage><lpage>D1082</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id><?supplied-pmid 29126136?><pub-id pub-id-type="pmid">29126136</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weininger</surname><given-names>D</given-names></name></person-group><article-title>SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules</article-title><source>J Chem Inform Comput Sci.</source><year>1988</year><volume>28</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1021/ci00057a005</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>CA</given-names></name></person-group><article-title>Lead-and drug-like compounds: the rule-of-five revolution</article-title><source>Drug Discov Today.</source><year>2004</year><volume>1</volume><issue>4</issue><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>42717</fpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><?supplied-pmid 28256516?><pub-id pub-id-type="pmid">28256516</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naghipour</surname><given-names>S</given-names></name><name><surname>Ghodousi</surname><given-names>M</given-names></name><name><surname>Rahsepar</surname><given-names>S</given-names></name><name><surname>Elyasi</surname><given-names>S</given-names></name></person-group><article-title>Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine; from HIV-1 infection to COVID-19</article-title><source>Expert Rev Anti Infect Ther</source><year>2020</year><volume>18</volume><issue>11</issue><fpage>1119</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1792291</pub-id><?supplied-pmid 32631083?><pub-id pub-id-type="pmid">32631083</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GM</given-names></name><name><surname>Huey</surname><given-names>R</given-names></name><name><surname>Lindstrom</surname><given-names>W</given-names></name><name><surname>Sanner</surname><given-names>MF</given-names></name><name><surname>Belew</surname><given-names>RK</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><etal/></person-group><article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title><source>J Comput Chem</source><year>2009</year><volume>30</volume><issue>16</issue><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><?supplied-pmid 2760638?><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>DJ</given-names></name><name><surname>Tidor</surname><given-names>B</given-names></name></person-group><article-title>Systematic placement of structural water molecules for improved scoring of protein&#x02013;ligand interactions</article-title><source>Protein Eng Des Sel</source><year>2011</year><volume>24</volume><issue>10</issue><fpage>777</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1093/protein/gzr036</pub-id><?supplied-pmid 21771870?><pub-id pub-id-type="pmid">21771870</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Dallakyan S, Olson AJ (2015) Swmall-molecule library screening by docking with PyRx. In: Chemical biology. Humana Press, New York: Springer, pp 243&#x02013;250</mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000e4;hrrolfes</surname><given-names>R</given-names></name><name><surname>Bietz</surname><given-names>S</given-names></name><name><surname>Flachsenberg</surname><given-names>F</given-names></name><name><surname>Meyder</surname><given-names>A</given-names></name><name><surname>Nittinger</surname><given-names>E</given-names></name><name><surname>Otto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Proteins Plus: a web portal for structure analysis of macromolecules</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>W1</issue><fpage>W337</fpage><lpage>W343</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx333</pub-id><?supplied-pmid 28472372?><pub-id pub-id-type="pmid">28472372</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stierand</surname><given-names>K</given-names></name><name><surname>Maa&#x000df;</surname><given-names>PC</given-names></name><name><surname>Rarey</surname><given-names>M</given-names></name></person-group><article-title>Molecular complexes at a glance: automated generation of two-dimensional complex diagrams</article-title><source>Bioinformatics.</source><year>2006</year><volume>22</volume><issue>14</issue><fpage>1710</fpage><lpage>1716</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btl150</pub-id><?supplied-pmid 16632493?><pub-id pub-id-type="pmid">16632493</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salentin</surname><given-names>S</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>VJ</given-names></name><name><surname>Adasme</surname><given-names>MF</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name></person-group><article-title>PLIP: fully automated protein&#x02013;ligand interaction profiler</article-title><source>Nucleic Acids Res.</source><year>2015</year><volume>43</volume><issue>W1</issue><fpage>W443</fpage><lpage>W447</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv315</pub-id><?supplied-pmid 4489249?><pub-id pub-id-type="pmid">25873628</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Lou</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties</article-title><source>Bioinformatics.</source><year>2019</year><volume>35</volume><issue>6</issue><fpage>1067</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty707</pub-id><?supplied-pmid 30165565?><pub-id pub-id-type="pmid">30165565</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghose</surname><given-names>AK</given-names></name><name><surname>Viswanadhan</surname><given-names>VN</given-names></name><name><surname>Wendoloski</surname><given-names>JJ</given-names></name></person-group><article-title>A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</article-title><source>J Comb Chem</source><year>1999</year><volume>1</volume><issue>1</issue><fpage>55</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1021/cc9800071</pub-id><?supplied-pmid 10746014?><pub-id pub-id-type="pmid">10746014</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muegge</surname><given-names>I</given-names></name><name><surname>Heald</surname><given-names>SL</given-names></name><name><surname>Brittelli</surname><given-names>D</given-names></name></person-group><article-title>Simple selection criteria for drug-like chemical matter</article-title><source>J Med Chem</source><year>2001</year><volume>44</volume><issue>12</issue><fpage>1841</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1021/jm015507e</pub-id><?supplied-pmid 11384230?><pub-id pub-id-type="pmid">11384230</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnott</surname><given-names>JA</given-names></name><name><surname>Planey</surname><given-names>SL</given-names></name></person-group><article-title>The influence of lipophilicity in drug discovery and design</article-title><source>Expert Opin Drug Discov</source><year>2012</year><volume>7</volume><issue>10</issue><fpage>863</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1517/17460441.2012.714363</pub-id><?supplied-pmid 22992175?><pub-id pub-id-type="pmid">22992175</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrand</surname><given-names>JH</given-names></name></person-group><article-title>Solubility. xii. Regular solutions1</article-title><source>J Am Chem Soc.</source><year>1929</year><volume>51</volume><issue>1</issue><fpage>66</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1021/ja01376a009</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>SF</given-names></name></person-group><article-title>Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition</article-title><source>Xenobiotica.</source><year>2008</year><volume>38</volume><issue>7-8</issue><fpage>802</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1080/00498250701867889</pub-id><?supplied-pmid 18668431?><pub-id pub-id-type="pmid">18668431</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>ML</given-names></name></person-group><article-title>P-glycoprotein inhibition for optimal drug delivery</article-title><source>Drug Target Insights</source><year>2013</year><volume>7</volume><fpage>DTI</fpage><lpage>S12519</lpage><pub-id pub-id-type="doi">10.4137/DTI.S12519</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khushbu</surname><given-names>C</given-names></name><name><surname>Roshni</surname><given-names>S</given-names></name><name><surname>Anar</surname><given-names>P</given-names></name><name><surname>Carol</surname><given-names>M</given-names></name><name><surname>Mayuree</surname><given-names>P</given-names></name></person-group><article-title>Phytochemical and therapeutic potential of Piper longum Linn a review</article-title><source>Intern J Res Ayurveda Pharm</source><year>2011</year><volume>2</volume><issue>1</issue><fpage>157</fpage><lpage>161</lpage></element-citation></ref></ref-list></back></article>